Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMC6156
- Development stage
- Phase 2
- Lead developer
- Animuscure
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AMC6156 is an investigational small molecule drug developed for the treatment of **sarcopenia** in older adults. Its mechanism of action and molecular target are undisclosed in public sources, but it is undergoing Phase 2 clinical trials to assess its efficacy in improving physical function, muscle mass, and strength in elderly patients with sarcopenia. The drug is administered orally, and clinical trials are evaluating various dosages over a 12-week period with endpoints including improvements in the Short Physical Performance Battery (SPPB), muscle mass, grip strength, and quality of life.
02
Targets
CDO1 (Cysteine dioxygenase type 1)PPAR (PPAR family)
Beyond the preview
Go deeper on AMC6156.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMC6156.